目的:根据眼表疾病指数(OSDI)评估眼表生态系统假体置换(BostonSightPROSE)治疗对症状结局的影响。
方法:这是一个单中心,回顾性分析2017年9月至2019年12月期间由同一临床医生开始PROSE治疗的连续患者.主要结果指标是比较PROSE治疗前和随访时的基线OSDI调查评分,经过PROSE治疗。治疗指征,性别,年龄,装置直径,平均磨损时间,预先存在的精神疾病,PROSE磨损的持续时间,并对随访中的PROSE磨损状况进行了研究。
结果:在研究期间,共有134名患者接受了PROSE治疗并完成了基线OSDI调查。43例患者完成了OSDI随访调查,并纳入研究分析。最常见的治疗指征是干燥性角膜结膜炎(n=27)和角膜扩张(n=16)。完成后续OSDI调查的43名受试者的基线平均OSDI评分为56.9±23.7。最后记录的43名受试者的平均随访OSDI为23.8±15.6,中位数(IQR)为22.9(10.4至32.3),与基线相比有统计学显著的54.7±27.6%的平均改善(p<0.01)。所有患者,除了两个,显示OSDI评分改善。无论基础诊断如何,均发生了统计学上的显着改善,基于年龄没有统计学上的显着差异,性别,精神疾病,或设备直径,与平均磨损时间没有统计相关性,或PROSE磨损的持续时间。
结论:如OSDI调查所示,PROSE治疗可改善视功能和症状缓解。性,年龄,预先存在的精神疾病,装置直径,平均磨损时间,和磨损持续时间对OSDI结果无统计学显著影响。
OBJECTIVE: To evaluate the impact of prosthetic replacement of the ocular surface ecosystem (BostonSight
PROSE) treatment on symptom outcomes based on the Ocular Surface Disease Index (OSDI).
METHODS: This was a single-center, retrospective analysis of consecutive patients who initiated
PROSE treatment between September 2017 and December 2019 by the same clinician. The primary outcome measure was to compare OSDI survey scores at baseline prior to
PROSE treatment and at follow-up, after
PROSE treatment. Indication for treatment, sex, age, device diameter, average wear time, preexisting mental illness, duration of PROSE wear, and status of
PROSE wear at follow-up were also studied.
RESULTS: A total of 134 patients underwent PROSE treatment and completed a baseline OSDI survey during the study period. Forty-three patients completed a follow-up OSDI survey and were included in the study analysis. The most common treatment indications were keratoconjunctivitis sicca (n=27) and corneal ectasia (n=16). Baseline average OSDI score was 56.9±23.7 for the 43 subjects who completed a subsequent OSDI survey. The last documented average follow-up OSDI for those 43 subjects was 23.8±15.6, median (IQR) of 22.9 (10.4 to 32.3), and a statistically significant 54.7±27.6% average improvement from baseline (p<0.01). All patients, except for two, showed improvement in OSDI score. Statistically significant improvement occurred regardless of underlying diagnosis with no statistically significant difference based on age, sex, mental illness, or device diameter and no statistical correlation with average wear time, or duration of PROSE wear.
CONCLUSIONS: PROSE treatment improves visual function and symptom relief as demonstrated by the OSDI survey. Sex, age, preexisting mental illness, device diameter, average wear time, and duration of wear had no statistically significant impact on OSDI outcomes.